Expiration Date Extension for North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin) Lot CL6814 through June 30, 2025

This is to provide you with important information regarding Antivenin (Micrurus fulvius) (Equine Origin), commonly referred to as North American Coral Snake Antivenin. Antivenin (Micrurus fulvius) (Equine Origin) is indicated for treatment of envenomation by Micrurus fulvius fulvius (Eastern Coral Snake) and Micrurus fulvius tenere (Texas Coral Snake).

Coral Snake Antivenom product was manufactured by Wyeth Pharmaceuticals, now a wholly owned subsidiary of Pfizer, Inc. FDA has extended the expiration date on this Lot CL6814 of Antivenin (Micrurus fulvius) (Equine Origin), from June 30, 2024, to June 30, 2025. The extension is based upon FDA evaluation of stability data, which determined that this lot will maintain stability and potency for an additional year after the current expiration date of June 30, 2024.

There is no alternative product licensed in the U.S. for coral snake envenomation. Lot CL6814 is labeled with an expiration date of June 30, 2024.

Lot CL6814 continues to be available, and Wyeth is closely managing their inventory.